SCHEMBL62756

SCHEMBL62756

O=C1[C]Cc2ccccc2O1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 3/20 0.46
MAOB P27338 2/20 0.46
GAA P10253 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CYP1A2 P05177 1/20 0.34
RAB9A P51151 2/20 0.33
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PKM P14618 1/20 0.32
TSHR P16473 1/20 0.32
SIRT1 Q96EB6 1/20 0.32
OXTR P30559 1/20 0.31
CES1 P23141 1/20 0.31
MAPKAPK2 P49137 1/20 0.31
ALOX15 P16050 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
ABCG2 Q9UNQ0 1/20 0.31
ITGB2 P05107 1/20 0.31
ICAM1 P05362 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8314956 0.80 MAOA (0.43) MAOAMAOBGAANPSR1CYP1A2
SCHEMBL7869058 0.67 MAOA (0.73) MAOAMAOBGAANPSR1CYP1A2
SCHEMBL44758 0.67 MAOA (0.65) MAOAMAOBGAANPSR1CYP1A2
SCHEMBL30487859 0.67 MAOA (0.65) MAOAMAOBGAANPSR1CYP1A2
SCHEMBL29364777 0.67 MAOA (0.65) MAOAMAOBGAANPSR1CYP1A2
SCHEMBL10462577 0.67 MAOA (0.73) MAOAMAOBGAANPSR1CYP1A2
SCHEMBL334750 0.67 MAOA (0.46) MAOAMAOBGAANPSR1RAB9A
SCHEMBL10338680 0.65 MAOA (0.70) MAOAMAOBGAANPSR1CYP1A2
Dihydrocoumarin SCHEMBL17629427 0.65 MAOB (0.50) MAOAMAOBGAANPSR1CYP1A2
SCHEMBL57888 0.65 MAOA (0.62) MAOAMAOBGAANPSR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1520 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572384-B2 Unusual substrates of tubulin tyrosine ligase FORSCHUNGSVERBUND BERLIN E.V. (DE) 2023-02-07 US claimed
CN-106795174-B Antiviral active diazacyclospirodiketopiperazine alkaloid derivative and preparation method thereof 扬州蓝色生物医药科技有限公司 2020-04-28 CN claimed
US-20190144493-A1 UNUSUAL SUBSTRATES OF TUBULIN TYROSINE LIGASE FORSCHUNGSVERBUND BERLIN E.V. (DE) 2019-05-16 US claimed
WO-2017186855-A1 UNUSUAL SUBSTRATES OF TUBULIN TYROSINE LIGASE FORSCHUNGSVERBUND BERLIN E.V. (DE) 2017-11-02 WO claimed
EP-2252300-B1 USE OF 2,4-PYRIMIDINEDIAMINES FOR THE TREATMENT OF ATHEROSCLEROSIS RIGEL PHARMACEUTICALS INC (US) 2016-10-19 EP claimed
WO-2016123709-A1 FLUORINATED IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS INHIBITORS OF BROMODOMAIN CONTAINING PROTEINS TRILLIUM THERAPEUTICS INC. (CA) 2016-08-11 WO claimed
EP-2091527-B1 SULFIDE, SULFOXIDE AND SULFONE CHALCONE ANALOGUES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF UNIV TEMPLE (US) 2016-03-23 EP claimed
EP-1660464-B1 CASPASE INHIBITORS CONTAINING ISOXAZOLINE RING LG LIFE SCIENCES LTD (KR) 2015-02-25 EP claimed
US-8557806-B2 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds RIGEL PHARMACEUTICALS, INC. (US) 2013-10-15 US claimed
US-20120230984-A1 Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds RIGEL PHARMACEUTICALS, INC. (US) 2012-09-13 US claimed
US-6337394-B2 N-ACYL-HETEROCYCLE-CARBOXYAMIDES THAT ARE N-SUBSTITUTED WITH AMIDINO-SUBSTITUTED RINGS; COMPETITIVE INHIBITORS OF THROMBIN; ANTICOAGULANTS ASTRAZENECA AB (SE) 2002-01-08 US claimed
US-20010046981-A1 COMPOUNDS ASTRA AKTIEBOLAG (SE) 2001-11-29 US claimed
US-6255301-B1 CARDIOVASCULAR DISORDERS; ANTICOAGULANT; PROTEASE INHIBITORS ASTRAZENECA AB (SE) 2001-07-03 US claimed
EP-1073449-A1 AMINO ACID AMIDINOHYDRAZONES, ALKOXYGUANIDINES AND AMINOGUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2001-02-07 EP claimed
EP-1036061-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2000-09-20 EP claimed
WO-1999055355-A1 AMINO ACID AMIDINOHYDRAZONES, ALKOXYGUANIDINES AND AMINOGUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1999-11-04 WO claimed
WO-1999029664-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 1999-06-17 WO claimed
EP-0910573-A1 NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS Astra Aktiebolag (SE) 1999-04-28 EP claimed
EP-0836384-A1 ARTHROPODICIDAL AND FUNGICIDAL CYCLIC AMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1998-04-22 EP claimed
WO-1997046577-A1 NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS ASTRA AKTIEBOLAG (SE) 1997-12-11 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010046981-A1 COMPOUNDS F2, SERPINC1, SERPINB1 MAOA 590/4885MAOB 149/4885GAA 433/4885
US-11572384-B2 Unusual substrates of tubulin tyrosine ligase TTL, TUBA1C, TUBB6 MAOA 3030/4885MAOB 3302/4885GAA 2071/4885
US-20190144493-A1 UNUSUAL SUBSTRATES OF TUBULIN TYROSINE LIGASE TTL, TUBA1C, TUBB6 MAOA 3030/4885MAOB 3302/4885GAA 2071/4885
US-20120230984-A1 Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds SSB, TYMS, TPMT MAOA 1493/4885MAOB 864/4885GAA 673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.